What changed: Pancreatic neuroendocrine tumours
Every dated change on the records linked to Pancreatic neuroendocrine tumours, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval5Regulatory1Trial result4Milestone10This record1
September 2026 · 1
2026 · 1
2025 · 3
2024 · 2
- 2024Trial resultCABINET (Alliance A021602)CABINET (Alliance A021602) reported
PFS HR 0.
- 2024MilestoneStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETNETTER-2: first-line lutetium-177 dotatate in grade 2 to 3 disease; CABINET pancreatic cohort published
A milestone in how this cancer is treated.
2023 · 1
2021 · 1
January 2018 · 1
2018 · 1
2017 · 1
2016 · 1
2014 · 1
2011 · 4
- 2011ApprovalEverolimusEverolimus approved in US
Progressive pancreatic NETs
- 2011ApprovalSunitinibSunitinib approved in US
Progressive pancreatic NETs
- 2011Trial resultRADIANT-3 and RADIANT-4RADIANT-3 and RADIANT-4 reported
PFS HR 0.
- 2011MilestoneRADIANT-3 and RADIANT-4RADIANT-3 and the sunitinib phase 3 published; everolimus and sunitinib approved; MEN1, DAXX and ATRX mutations mapped by exome sequencing
A milestone in how this cancer is treated.